Optimizing criteria for N-terminal pro-B-type natriuretic peptide for eligibility and enrichment in trials in heart failure with preserved, mid-range and reduced ejection fraction
27 May 2018 (08:30 - 18:00)
Organised by:
Abstract
About the speaker

Karolinska Institute, Stockholm (Sweden)
5 More presentations in this session
Access the full session
The Event
Heart Failure 2018
27 May 2018
08:30 CET
